Xyntha represents the first new therapeutic option introduced to the hemophilia community since 2003.

Cleviprex, is a novel IV antihypertensive, represents an advancement over currently available therapies.

Pentacel, a new pediatric combination vaccine from Sanofi Pasteur, the vaccines division of the Sanofi Aventis Group, was licensed by the FDA on June 23, 2008.

FUSILEV(TM) is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists.

Prestwick Pharmaceuticals, which owns the North American commercial rights to Xenazine, is seeding the market in preparation for the orphan drug's US launch, which is expected by year end.

NovoNordisk's PrandiMet will be sold by diabetes reps from Sciele Pharma, who already carries one half of the combo pill in their bags.

"One less ouch" is the tag line for this new pediatric booster vaccine from GlaxoSmithKline.

Alcon, which has staked out a position in treating ocular allergies, hopes Patanase extends the franchise beyond eyes.

The Omnaris brand of ciclesonide, a nasal spray, follows on the heels of another ciclesonide product that Sepracor launched earlier this year—inhaled corticosteroid Alvesco.

Adolor/GlaxoSmithKline's Entereg finally received approval for post-operative ileus (POI), but safety concerns have put a more lucrative potential indication, opioid-induced bowel dysfunction (OBD), out of reach.